In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68

Immunopharmacology

Volumn 35, Issue 1, 1996, Pages 41-46

  Mihara, Masahiko ^a   Urakawa, Kazumi ^a   Takagi, Nobuhiro ^a   Moriya, Yoichiro ^a   Takeda, Yasuhisa ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

cell proliferation; collagen induced arthritis; mouse; MTX; MX 68; polyglutamation

Indexed keywords

ANTIRHEUMATIC AGENT; COLLAGEN TYPE 2; FOLIC ACID ANTAGONIST; FOLINIC ACID; IONOMYCIN; METHOTREXATE; N [[4 [(2,4 DIAMINO 6 PTERIDINYL)METHYL] 3,4 DIHYDRO 2H 1,4 BENZOTHIAZIN 7 YL]CARBONYL]HOMOGLUTAMIC ACID; NEW DRUG; PHORBOL 13 ACETATE 12 MYRISTATE; PHYTOHEMAGGLUTININ; POLYGLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

EID: 0030273493     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(96)00117-8     Document Type: Article

References (20)

1. Alarcon, G.S., Castaneda, O., Ferrandiz, M., Krumdieck, C.L. and Koopman, W.J. 1992. Efficacy and safety of 10-deazaaminopterin in the treatment of rheumatoid arthritis. Arthritis Rheum. 35: 1318-1321.
2. Allegra, C,J., Drake, J.C., Jolivet, J. and Chabner, B.A. 1984. Inhibition of folate-dependent enzymes by methotrexate polyglutamates. In: ed. I.D. Goldman, Proc. of the Second Workshop on Folyl and Antifolyl Polyglutamates. Pergamon Press, Oxford, 348-359.
3. Anderson P.A., West, S.G., O'Dell, J.R., Via, C.S., Claypool, R.G. and Kotzin, B.L., 1985. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunological effects in a randomized, double-blind study. Ann. Intern. Med. 103: 489-496.
4. Baggott, J.E., Vaughn, W.H. and Hudson, B.B., 1986. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosin deaminase, and 5'-adenylate deaminase by poly glutamates of methotrexate and oxidized folates and by 5'-aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J. 236: 193-200.
5. Baggott, J.E., Morgan, S.L., Ha, T.-S., Alarcon, G.S., Koopman, W.J. and Krumdieck C.L., 1993. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin. Exp. Rheumatol. 11: S101-S105.
6. Baugh, C.M., Krumdieck, C.L. and Nair, M.G., 1973. Polygammaglutamyl metabolites of methotrexate. Biochem. Biophys. Res. Commun. 52: 27-34.
7. Beardsley, G.P., Moroson, B.A., Taylor, B.C. and Moran, R.G., 1989. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J. Biol. Chem. 264: 328-333.
8. Brennan, F.M., Chantry, D., Jackson, A.M., Maini, R.N. and Feldmann, M., 1989. Cytokine production in culture by cells isolated from the synovial membrane. J. Autoimmun. 2: 177-186.
9. Chabner, B,A., Allegra, C.J., Curt, G.A., Clendeninn, N.J., Baram, J., Koizumi, S., Drake, J.C. and Jolivet, J., 1985. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76: 907-912.
10. Hirata, S., Matsubara, T., Saura, R., Tateishi, H. and Hirohata, K., 1989. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32: 1065-1073.
11. Jackman, A.L., Taylor, G.A., O'Connor, B.M., Bishop, J.A., Moran, R.G. and Calvert, A.H., 1990. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-di-deazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res. 50: 5212-5218.
12. Kremer J.M. and Phelps, C.T., 1992. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 35: 138-145.
13. Mihara, M., Katsume, A. and Takeda, Y., 1992. Effect of methotrexate treatment on the onset of autoimmune kidney disease in lupus mice. Chem Pharm Bull 40: 2177-2181.
14. Oslen N.J. and Murray L.M., 1989. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum. 32: 378-385.
15. Rau, R., Herborn, G., Karger, T., Manninger, H., Elhardt, D. and Schmitt, J., 1991. A double blind randomized trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J. Rheumatol. 18: 328-333.
16. Rosenthal, G.J., Germolec, D.R., Lamm, K.R., Ackermann, M.F. and Luster, M.I., 1987. Comparative effects on the immune system of methotrexate and trimetrexate. Int. J. Immunopharmacol. 9: 793-801.
17. Segal A.M. and Wilke, W.S., 1989. Toxicity of low-dose methotrexate in rheumatoid arthritis. In: ed. W.S. Wilke, Methotrexate Therapy in Rheumatic Disease. Marcel Dekker, Basel, 147-178.
18. Weinblatt, M.E., Coblyn, J.S., Fox, D.A., Holdsworth, D.E., Glass, D.N. and Trentham, D.E., 1985. Efficacy of low-dose methotrexate in rheumatoid arthritis. New Engl. J. Med. 312: 818-822.
19. Weinblatt, M.E., Weissman, B.N., Holdsworth, D.E., Fraser, P.A., Maier, A.L., Falchuk, K.R. and Coblyn, J.S., 1992. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 35: 129-137.
20. Willkens, R.F., Urowitz, M.B., Stablein, D.M., McKendry, R.J.R., Berger, R.G., Box, J.H., Fiechtner, J.J., Fudman, E.J., Hudson, N.P., Marks, C.R., Brooks, R., Rooeny, T., Rubin, B.R., Schmid, F.R., Segal, A.M., Thomas, J.W., Goldstein, A.G., Yunus, M.B., Wortmann, R.L. and Sherrer, T.R.S., 1992. Comparison of azathioprine, methotrexate and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 35: 849-856.